Aug 13, 2026 08:00AM
Aug 5, 2026 09:07AM
Aug 5, 2026 08:00AM
Aug 2, 2026 07:30PM
Aug 2, 2026 07:30PM
May 31, 2026 07:30PM
May 12, 2026 08:00AM Ascentage Pharma to Participate in Three Upcoming Investor Conferences
Feb 9, 2026 08:00AM
Feb 5, 2026 06:30PM
Feb 5, 2026 06:30PM
Jan 14, 2026 08:25PM
Dec 17, 2025 08:00AM
Dec 8, 2025 07:45PM
Dec 8, 2025 07:45PM ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
Dec 8, 2025 07:45PM
Dec 7, 2025 08:10PM
Dec 6, 2025 10:15AM
Dec 4, 2025 07:00PM
Dec 1, 2025 08:00AM
Nov 24, 2025 07:00PM
Nov 19, 2025 08:00AM Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
Nov 3, 2025 08:10PM
Nov 3, 2025 08:10PM
Oct 29, 2025 08:00PM
Oct 7, 2025 08:00AM
Aug 25, 2025 08:00AM
Aug 20, 2025 07:57PM
Aug 17, 2025 07:30PM Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
Aug 7, 2025 08:00AM
Aug 1, 2025 08:00AM
Jul 23, 2025 08:00AM
Jul 17, 2025 04:30AM
Jul 14, 2025 10:36AM
Jul 14, 2025 10:35AM
Jul 14, 2025 05:23AM Ascentage Pharma Announces Proposed Top-Up Placement
Jul 10, 2025 09:30AM
Jul 7, 2025 07:30PM
Jun 15, 2025 07:30PM
Jun 9, 2025 07:30PM
Jun 2, 2025 07:30PM
Jun 2, 2025 07:30PM
May 22, 2025 08:15PM Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
Apr 23, 2025 07:00PM
Apr 21, 2025 07:00AM
Mar 25, 2025 07:00PM
Mar 5, 2025 06:00PM
Dec 26, 2024 08:29PM
Dec 10, 2024 09:27AM
Dec 10, 2024 09:17AM Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
Dec 10, 2024 08:26AM

328,820 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All